Switching to Quetiapine After Rexalti-Induced EPS
Yes, switching to quetiapine (Seroquel) would be a reasonable lower-risk alternative for EPS, though all antipsychotics carry significant risks in dementia patients and should be used cautiously at the lowest effective dose.
EPS Risk Profile: Quetiapine vs. Brexpiprazole
Quetiapine has a demonstrably lower propensity for extrapyramidal symptoms compared to most antipsychotics, including brexpiprazole (Rexalti). The FDA label data shows:
- Brexpiprazole in dementia patients: EPS-related adverse events occurred in 5.3% vs. 3.1% for placebo, with akathisia specifically noted as a common side effect 1
- Quetiapine: The FDA label notes that EPS can occur but emphasizes sedation/somnolence as the primary neurological concern rather than movement disorders 2
Research directly supports quetiapine's favorable EPS profile. A 2008 study demonstrated that switching to quetiapine significantly reduced pre-existing parkinsonism (p<0.001), akathisia (p=0.02), and dyskinesia (p<0.05) in patients with schizophrenia who had neuroleptic-induced movement disorders 3. This provides strong evidence that quetiapine can actually improve EPS when substituted for other antipsychotics.
Practical Switching Strategy
When switching from brexpiprazole to quetiapine in a dementia patient with agitation:
- Start low: Begin quetiapine at 25-50 mg/day, as elderly dementia patients in trials used mean doses of only 77 mg/day 4
- Titrate slowly: Increase by 25 mg every 3-7 days based on response and tolerability
- Target dose: 100-200 mg/day has shown efficacy for agitation in dementia 5, though lower doses may suffice
- Cross-taper: Can directly switch or briefly overlap given different receptor profiles
Critical Safety Considerations
Mortality Risk (Black Box Warning)
Both medications carry the FDA black box warning for increased mortality in elderly dementia patients 6, 2. Guidelines emphasize this applies to the entire class 6, 7. However, when dangerous agitation threatens patient or caregiver safety, antipsychotic use may be justified after weighing risks and benefits with the family 6.
Quetiapine-Specific Risks in Elderly
- Orthostatic hypotension and falls: More prominent than with brexpiprazole due to alpha-1 blockade 2
- Sedation: Can be excessive, particularly during titration 2
- Cognitive effects: Monitor with MMSE, though studies show no significant worsening 4
- Metabolic effects: Less concerning at low doses used in dementia
Comparative Head-to-Head Data
A 2007 study directly comparing quetiapine vs. risperidone in elderly dementia patients found no significant differences in EPS incidence between the two agents, with both being well-tolerated at low doses 4. This suggests quetiapine's EPS advantage is most apparent compared to higher-potency agents.
Alternative Considerations
If quetiapine fails or is poorly tolerated:
- Re-attempt brexpiprazole at lower dose: The 2-3 mg doses used in trials may be reducible; some patients tolerated 0.5-1 mg 8
- Non-pharmacologic interventions: Should be maximized first per guidelines 6, 7
- Discontinuation trial: If agitation is not severe or dangerous, consider stopping antipsychotics entirely given modest efficacy and significant risks 6
Monitoring After Switch
- EPS assessment: Use objective scales (Simpson-Angus, Barnes Akathisia) at baseline and 2-4 weeks
- Orthostatic vital signs: Check at each dose increase
- Falls assessment: Weekly for first month
- Cognitive function: MMSE at baseline and 4-8 weeks
- Efficacy: Cohen-Mansfield Agitation Inventory or similar tool
The evidence supports quetiapine as having lower EPS liability than brexpiprazole, making it a rational switch in this clinical scenario, provided you carefully monitor for quetiapine's distinct side effect profile (sedation, hypotension, falls) which may be more problematic than the EPS you're trying to avoid.